And Pfizer published data showing that the vaccine, which it produced in cooperation with the German Biontech, is 100 percent effective against infection in children aged 12-15 years, 4 months after the second dose.
She said the results of the third clinical trial showed no serious side effects or safety concerns.
Last May, the US authorities granted permission for the emergency use of the vaccine for adolescents and children, and Pfizer hopes that this data, which will be sent to the Food and Drug Administration, will help grant full approval for the use of the vaccine.
Fierz also hopes the findings will convince about a third of American parents, who have yet to refuse to give their children the vaccine.
The CEO of German Biontech, Ugur Sahin, said that this data is the first and only that has been disclosed, regarding the safety and efficacy of the vaccine for children aged 12-15 years.
“The accumulated data from the trials we conducted and the observations we actually carried out reinforce the evidence that the vaccine is effective and safe for children and adolescents,” he added.
The trial included 2,228 children in the United States, where half of the group received two doses of the vaccine three weeks apart, while the other half received two dummy doses.
Among the participants, 30 confirmed cases with symptoms of “Covid-19” disease caused by the Corona virus without evidence of previous infection, all of them in the placebo group.
This is consistent with a vaccine’s 100 percent efficacy, according to Pfizer’s data, which said the vaccine’s efficacy remained strong regardless of gender, race and obesity.
The main concern about vaccine side effects among this age group was myocarditis, a rare type of heart infection that affects young males under the age of 30.
The data showed that such cases are very rare, while the benefits of vaccination still greatly outweigh the risks.
.